Based on our results and combined with the experience of glioma immunotherapy, targeting macrophages/CD8+ TILs with anti-PD-L1 or other types of immune checkpoint inhibitors may provide a breakthrough in immunotherapy for aggressive PA. This evidence concerns the gene CD274 and central nervous system cancer.